Immune Cells from Pluripotent Stem Cells

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 1359

Special Issue Editor


E-Mail Website
Guest Editor
1. Associate Professor, Department of Biochemistry, School of Medicine & Biomedical Science, CHA University, Seongnam-si 13488, Gyeonggi-do, Republic of Korea
2. Director, Cell Therapy 3 Center, CHA Advanced Research Institute, CHA Bundang Medical Center, Sungnam-si 13488, Gyeonggi-do, Republic of Korea
Interests: pluripotent stem cells; hematopoietic stem cells; immune cells; megakaryocytes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immune cells exhibit diverse functions such as maintaining homeostasis, defense against pathogens, and regulating immune responses. Immune cells include T cells, B cells, macrophages, natural killer (NK) cells, dendritic cells, and even platelets. These are differentiated from hematopoietic stem cells.

Recently, with the commercialization of CAR-T cells for cancer treatment, interest in immune cell therapy is increasing. However, immune cells isolated from the human body have several limitations, including availability, variability between donors, and challenges in large-scale manufacturing.

Pluripotent stem cells (PSCs) offer a promising alternative due to their unlimited self-renewal and ability to differentiation into various cell types under appropriate conditions. PSCs can also be genetically engineered and differentiated into different immune cell types, potentially overcoming limitations of primary immune cells.

This Special Issue will examine the methods of differentiation and efficacy in vitro and in vivo of immune cells from PSCs.

Prof. Dr. Eunju Kang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pluripotent stem cells
  • T cells
  • B cells
  • macrophages
  • natural killer (NK) cells
  • dendritic cells
  • megakaryocytes
  • platelets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1566 KB  
Review
Integrating Macrophages into Human-Engineered Cardiac Tissue
by Yi Peng Zhao and Barry M. Fine
Cells 2025, 14(17), 1393; https://doi.org/10.3390/cells14171393 - 6 Sep 2025
Viewed by 693
Abstract
Heart disease remains a leading cause of morbidity and mortality worldwide, necessitating the development of in vivo models for therapeutic development. Advances in biomedical engineering in the past decade have led to the promising rise of human-based engineered cardiac tissues (hECTs) using novel [...] Read more.
Heart disease remains a leading cause of morbidity and mortality worldwide, necessitating the development of in vivo models for therapeutic development. Advances in biomedical engineering in the past decade have led to the promising rise of human-based engineered cardiac tissues (hECTs) using novel scaffolds and pluripotent stem cell derivatives. This has led to a new frontier of human-based models for improved preclinical development. At the same time, there has been significant progress in elucidating the importance of the immune system and, in particular, macrophages, particularly during myocardial injury. This review summarizes new methods and findings for deriving macrophages from human pluripotent stem cells (hPSCs) and advances in integrating these cells into cardiac tissue. Key challenges include immune cell infiltration in 3D constructs, maintenance of tissue architecture, and modeling aged or diseased cardiac microenvironments. By integrating immune components, hECTs can serve as powerful tools to unravel the complexities of cardiac pathology and develop targeted therapeutic strategies. Full article
(This article belongs to the Special Issue Immune Cells from Pluripotent Stem Cells)
Show Figures

Figure 1

Back to TopTop